Fotino Carmen, Ricordi Camillo, Lauriola Vincenzo, Alejandro Rodolfo, Pileggi Antonello
Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL 33136,USA.
Rev Diabet Stud. 2010 Summer;7(2):144-57. doi: 10.1900/RDS.2010.7.144. Epub 2010 Aug 10.
The bone marrow is an invaluable source of adult pluripotent stem cells, as it gives rise to hematopoietic stem cells, endothelial progenitor cells, and mesenchymal cells, amongst others. The use of bone marrow-derived stem cell (BMC) transplantation (BMT) may be of assistance in achieving tissue repair and regeneration, as well as in modulating immune responses in the context of autoimmunity and transplantation. Ongoing clinical trials are evaluating the effects of BMC to preserve functional beta-cell mass in subjects with type 1 and type 2 diabetes, and to favor engraftment and survival of transplanted islets. Additional trials are evaluating the impact of BMT (i.e., mesenchymal stem cells) on the progression of diabetes complications. This article reviews the progress in the field of BMC for the treatment of subjects with insulin-dependent diabetes, and summarizes clinical data of pilot studies performed over the last two decades at our research center by combining allogeneic islet transplantation with donor-specific BMC. Clinical data is summarized from pilot studies performed at our research center over the last two decades.
骨髓是成年多能干细胞的宝贵来源，因为它能产生造血干细胞、内皮祖细胞和间充质细胞等。使用骨髓来源的干细胞（BMC）移植（BMT）可能有助于实现组织修复和再生，以及在自身免疫和移植背景下调节免疫反应。正在进行的临床试验正在评估BMC对1型和2型糖尿病患者保留功能性β细胞量的影响，以及促进移植胰岛的植入和存活。其他试验正在评估BMT（即间充质干细胞）对糖尿病并发症进展的影响。本文综述了BMC治疗胰岛素依赖型糖尿病领域的进展，并总结了过去二十年在我们研究中心进行的试点研究的临床数据，这些研究将同种异体胰岛移植与供体特异性BMC相结合。临床数据总结自过去二十年在我们研究中心进行的试点研究。
